Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer
- 1 April 1985
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 14 (3) , 232-234
- https://doi.org/10.1007/bf00258122
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patientsCancer Chemotherapy and Pharmacology, 1983
- The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancerCancer Chemotherapy and Pharmacology, 1982
- MEDROXYPROGESTERONE ACETATE (MAP) RELATIVE BIOAVAILABILITY AFTER SINGLE HIGH-DOSE ADMINISTRATION IN CANCER-PATIENTS1982
- Medroxyprogesterone Acetate (MPA) Plasma Levels After Oral and Intramuscular Administration in A Long‐Term StudyActa Obstetricia et Gynecologica Scandinavica, 1981
- Pharmacokinetics of Medroxyprogesterone Acetate Administered by Oral and Intramuscular RouteActa Obstetricia et Gynecologica Scandinavica, 1981
- Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinomaActa Obstetricia et Gynecologica Scandinavica, 1979
- Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of depo-provera® to womenContraception, 1976
- Pharmacokinetic observations on medroxyprogesterone acetate administered orally and intravaginallyContraception, 1976
- GLC Determination of Medroxyprogesterone Acetate in PlasmaJournal of Pharmaceutical Sciences, 1974